Title:
NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC
Document Type and Number:
Japanese Patent JP2022130482
Kind Code:
A
Abstract:
To provide peptides, nucleic acids, and cells for use in immunotherapeutic methods.SOLUTION: The present invention relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides. The peptide epitopes serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to more than 70 novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.SELECTED DRAWING: None
Inventors:
Weinschenk, Toni
Walther, Steffen
Fritche, jens
Song, collet
Jing, Hull Plate
Walther, Steffen
Fritche, jens
Song, collet
Jing, Hull Plate
Application Number:
JP2022096317A
Publication Date:
September 06, 2022
Filing Date:
June 15, 2022
Export Citation:
Assignee:
Immatics Biotechnology Gem Beher
International Classes:
C12N15/12; A61K35/15; A61K35/16; A61K38/19; A61K39/00; A61K39/39; A61K39/395; A61K47/64; A61K47/68; A61K48/00; A61P35/00; A61P37/04; A61P43/00; C07K7/06; C07K7/08; C07K14/725; C07K16/00; C07K19/00; C12N5/0783; C12N5/10; C12N15/62; C12N15/63; C12P21/02
Domestic Patent References:
| JP2013521789A | 2013-06-13 |
Attorney, Agent or Firm:
Takashi Shoji
Previous Patent: JPWO2022130481
Next Patent: Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord inju...
Next Patent: Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord inju...